Palisade Bio director buys $28,800 in PALI stock
Alpha Vantage · Investing.com Canada · · AI-summarised by FinFlash
Palisade Bio director Donald Allen Williams bought $28,800 of PALI stock across two transactions on October 1 and 2, 2026, leaving him with more than 1.59 million shares held directly. The stock is down 34% year-to-date, and InvestingPro analysis calls it overvalued versus Fair Value, though Raymond James initiated coverage with an Outperform rating and a $6.00 price target.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.